COMP <GO>
ERNA vs GRI // GROSS PROFIT MARGIN
Ernexa Therapeutics Inc. (NASDAQ) VS. GRI Bio Inc. (NASDAQ) • 15-METRIC TALLY: ERNA 2
— GRI 1
■ METRIC PARITY
LAST: $1.97 (-6.63%) • MKT CAP: $3.4M
gross-margins
—
LAST: $1.53 (-2.55%) • MKT CAP: $3.4M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ERNA VS. GRI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ERNA | GRI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | ERNA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.1 | 46.1 | -8.00 | GRI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.4M | $3.4M | $12.2K | ERNA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ERNA REV | GRI REV | ERNA GROSS % | GRI GROSS % | ERNA FCF | GRI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$7.1M | -$10.2M |
| FY 2024 | $582.0K | $0 | 83.5% | — | -$16.2M | -$8.6M |
| FY 2023 | $68.0K | $0 | — | — | -$20.4M | -$9.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ERNA // BETA —
GRI // BETA —